JP2008536853A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536853A5
JP2008536853A5 JP2008506668A JP2008506668A JP2008536853A5 JP 2008536853 A5 JP2008536853 A5 JP 2008536853A5 JP 2008506668 A JP2008506668 A JP 2008506668A JP 2008506668 A JP2008506668 A JP 2008506668A JP 2008536853 A5 JP2008536853 A5 JP 2008536853A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008506668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008536853A (ja
Filing date
Publication date
Priority claimed from US11/402,502 external-priority patent/US20060235006A1/en
Application filed filed Critical
Publication of JP2008536853A publication Critical patent/JP2008536853A/ja
Publication of JP2008536853A5 publication Critical patent/JP2008536853A5/ja
Withdrawn legal-status Critical Current

Links

JP2008506668A 2005-04-13 2006-04-13 癌治療のための、組み合わせ、方法および組成物 Withdrawn JP2008536853A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67074405P 2005-04-13 2005-04-13
US74843305P 2005-12-08 2005-12-08
US11/402,502 US20060235006A1 (en) 2005-04-13 2006-04-12 Combinations, methods and compositions for treating cancer
PCT/US2006/013773 WO2006113304A2 (en) 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer

Publications (2)

Publication Number Publication Date
JP2008536853A JP2008536853A (ja) 2008-09-11
JP2008536853A5 true JP2008536853A5 (https=) 2009-05-28

Family

ID=37109315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008506668A Withdrawn JP2008536853A (ja) 2005-04-13 2006-04-13 癌治療のための、組み合わせ、方法および組成物

Country Status (12)

Country Link
US (2) US20060235006A1 (https=)
EP (1) EP1868435A4 (https=)
JP (1) JP2008536853A (https=)
KR (1) KR20080004495A (https=)
AU (1) AU2006236812A1 (https=)
BR (1) BRPI0608176A2 (https=)
CA (1) CA2604581A1 (https=)
EA (1) EA200702238A1 (https=)
MX (1) MX2007012537A (https=)
NO (1) NO20075087L (https=)
TW (1) TW200722091A (https=)
WO (1) WO2006113304A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215901B1 (pl) * 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
ATE505192T1 (de) * 2005-06-09 2011-04-15 Bristol Myers Squibb Co Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス mTORインヒビター、ハーセプチン、および/またはHKI−272の抗悪性腫瘍性組み合わせ
US20090099197A1 (en) * 2005-11-15 2009-04-16 Bristol-Myers Squibb Company Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
EP2606890A1 (en) * 2006-04-05 2013-06-26 Novartis AG Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
CN101415426A (zh) * 2006-04-07 2009-04-22 诺瓦提斯公司 c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2222166B9 (en) * 2007-12-10 2012-11-07 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
CN105147713A (zh) * 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
EP2370175A2 (en) * 2008-12-16 2011-10-05 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
SMT201700293T1 (it) * 2009-07-20 2017-07-18 Bristol Myers Squibb Co Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative
JP2013505968A (ja) * 2009-10-01 2013-02-21 シーエスエル、リミテッド フィラデルフィア染色体陽性白血病の治療方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
PL215901B1 (pl) * 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
PT1392313E (pt) * 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
AU2003259717A1 (en) * 2002-08-07 2004-02-25 Bristol-Myers Squibb Company Modulators of rabggt and methods of use thereof
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
AR047530A1 (es) * 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases

Similar Documents

Publication Publication Date Title
JP2008536853A5 (https=)
JP2009502743A5 (https=)
JP2006523216A5 (https=)
JP2021063088A5 (https=)
JP2021526132A5 (https=)
JP2021191784A5 (https=)
JP2009545527A5 (https=)
JP2007145875A5 (https=)
JP2013507439A5 (https=)
JP2006514012A5 (https=)
JP2018507914A5 (https=)
JP2011500713A5 (https=)
IL193099A (en) Use of ferric citrate-containing preparations in the preparation of chronic kidney disease drugs
JP2013525444A5 (https=)
JP2004534850A5 (https=)
JP2010525056A5 (https=)
JP2006182786A5 (https=)
JP2015508103A5 (https=)
JP2007504174A5 (https=)
JP2015523397A5 (https=)
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
JP2008513510A5 (https=)
JP2008539267A5 (https=)
JP2008539268A5 (https=)
JP2007510667A5 (https=)